trump and glp 1 meds officials plan coverage for weight loss drugs under Medicare Medicaid | Trump administration Pres. Donald Trump announced that

Nakajima K, Nagamine T, Fujita MQ, Ai M, Tanaka A, Schaefer E

Regarding the vascular system, continuous infusion of the GLP-1 analog exendin-4 reduced monocyte adhesion to aortic endothelial cells, associated with a reduction in atherosclerotic lesion size in non-diabetic C57BL/6 and ApoE / mice

Mazdutide Oxyntomodulin is a proglucagon fragment that activates both GLP-1 and glucagon receptors

Psychiatry 18 (9), 961962

doi: 10.1001/jama.2024.0318

SAR441255, a recently developed triple-agonist based on the exendin-4 sequence, demonstrates improved glycemic control in healthy human subjects following a mixed meal test in a phase Ia single dose clinical trial